In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. - Wikidata - wikimedia - TriplyDB

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

http://www.wikidata.org/entity/Q40176521

about

Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation The STARD9/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole assembly Plk1 negatively regulates PRC1 to prevent premature midzone formation before cytokinesis.Two distinct cytokinesis pathways drive trypanosome cell division initiation from opposite cell ends.Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel PLK1, A Potential Target for Cancer Therapy Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.Phosphorylation of MyoGEF on Thr-574 by Plk1 promotes MyoGEF localization to the central spindle.PLK1 down-regulates parainfluenza virus 5 gene expression ATR activation and replication fork restart are defective in FANCM-deficient cells.Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.Preparation of orthogonally protected (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of Polo-box domain-binding peptides.Depsides isolated from the Sri Lankan lichen Parmotrema sp. exhibit selective Plk1 inhibitory activity.Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass.Plk1 negatively regulates Cep55 recruitment to the midbody to ensure orderly abscission Polo-like kinase 3 regulates CtIP during DNA double-strand break repair in G1.Identification of small-molecule inhibitors of the ribonuclease H2 enzyme.Investigation of unanticipated alkylation at the N(π) position of a histidyl residue under Mitsunobu conditions and synthesis of orthogonally protected histidine analogues.Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.Structure-function relationship of the Polo-like kinase in Trypanosoma brucei.Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.A Novel Basal Body Protein That Is a Polo-like Kinase Substrate Is Required for Basal Body Segregation and Flagellum Adhesion in Trypanosoma brucei Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration.Requirement for PLK1 kinase activity in the maintenance of a robust spindle assembly checkpoint Long noncoding RNA lnc-RI is a new regulator of mitosis via targeting miRNA-210-3p to release PLK1 mRNA activity.Polo-like kinase 1 is essential for early embryonic development and tumor suppression.Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.Requirements for protein phosphorylation and the kinase activity of polo-like kinase 1 (Plk1) for the kinetochore function of mitotic arrest deficiency protein 1 (Mad1).The development of targeted therapy in small cell lung cancer.Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.Mitosis as an anti-cancer drug target.Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.Current assessment of polo-like kinases as anti-tumor drug targets.Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.

P2860

Q21092524-029A04C9-342D-4C1F-965A-484D81C13C55 Q21092734-83780D80-EA29-41F2-973F-FEF80B08921F Q24299186-9989DBCA-27BB-4B17-8F88-770AD17692B9 Q24329251-C21C8FCA-EC9A-43D6-8B2F-02535DA0BDE9 Q27316118-47A589AE-2BD6-47BE-A138-AB371FB63D5F Q27670838-D9FC21F6-9C41-4E97-8DD2-32214B8D0A81 Q28078772-BFFF94CB-A62E-4D8E-80FF-CB5D0ECDDCFE Q28552326-D8FEFE5F-F92A-4229-9D60-10DED3584ACC Q30480149-6900C80F-8A50-4390-B365-40CADBC0E97E Q30484139-D8765E45-FE07-4D29-9360-7E84F6708B81 Q33486509-69104455-FEDA-4810-9A5B-89B10CD867C5 Q33522555-017D1D98-4978-4D79-84C5-72B557A5C8E4 Q33564389-43CB156B-FD33-4369-BD09-8FE64CE33B4C Q33771808-BA3DDD4E-7776-437F-B651-786CE16AFB82 Q33807668-9E2911C7-62B6-42A6-9DEB-8A43CCF91468 Q33829178-EA6ABF0D-B61D-4CA5-A0F7-EB8289CF7C50 Q34149971-876DFDF6-48EE-4C19-B6FC-7B391241FE82 Q34262604-CD6062FB-6F23-4081-9CBA-BB5BEF2D08BE Q34593795-2CFD24F2-FF26-47C0-90BB-D3D76896E328 Q35536433-349B8D42-17D3-48B2-B347-68E9388CA22C Q35801683-B5DD65D9-A0F1-46AC-9082-52127248AAB8 Q35832219-7DE39092-E229-470A-AC75-F7B755500AAD Q35832355-65350199-5DE2-4659-8FA9-D8F2077FAB66 Q35912449-BF65A075-D5AB-4489-A3B0-A11686EFE9B1 Q36054290-5E84C821-70DD-456F-8B82-F6A4BA846996 Q36062154-358E19D1-5236-4F14-B453-C245583BB89E Q36139900-C6F40CA6-F75E-4CD1-8E5C-70F3379B211A Q36293407-CA0622D2-E33C-4FF1-A4BB-F12D94E32F99 Q36408265-C41A1D2D-C118-4E30-8B90-B740659E0833 Q36506509-E6D571C7-21A4-4B98-9253-029A4AA886C0 Q36886156-F07F9A0A-E518-4124-AD89-1FD67F7CDB33 Q36949896-ADA42615-F718-4C44-8ECA-51C0763C2475 Q36976154-389CF361-FC55-4284-845E-48E28B4E8434 Q37015055-09DEAC28-98FF-4F93-8CF8-8421756062E8 Q37127932-09ED0E05-E7AA-48CF-ADBF-E3B20DF35BE4 Q37383729-E947A55A-1631-4940-83F2-312284860C10 Q38115166-6F50089D-7691-46E8-A6A2-542F832AAD34 Q38129174-8BEDDFC2-9B98-47E4-8EB2-8748B9FD01DA Q38211244-E0BD8BDE-3EE6-449B-9C30-F29AD041C09F Q38792069-C81701A5-BC79-490B-9FE8-FBFAC9FD7E7D

P2860

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

http://www.wikidata.org/entity/Q40176521

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

@en

type

label

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

@en

prefLabel

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

@en

P1433

Q40176521-76FF70E2-478D-4784-B1EC-EF76418347DE

P1476

Q40176521-61F4054F-6B3E-411A-B626-EB1750A1A788

P2093

Q40176521-09108952-E2F6-4CDD-9E11-F9403E167102

Q40176521-32B7B111-34B9-4BE4-9D78-30B4E1442CAF

Q40176521-45EAE57F-ACFA-47DB-BDEF-BAE54B854FB0

Q40176521-54575CC2-F7A5-4796-AE77-3B8DAE60559B

Q40176521-5CEC7187-CE36-41EE-AA2D-F655CCCF2EEF

Q40176521-7262D559-46B8-43A9-AFA2-26890A790842

Q40176521-8AEE7E48-55E5-4A38-9E2B-E23D76CA996C

Q40176521-9DF096F9-BE07-4377-BEED-EA568537DC64

Q40176521-A8267B24-0A2C-4AC0-BBCA-EBCE6709A0B6

Q40176521-ACE6AE52-5A30-4830-996D-72B0C9C738A9

P304

Q40176521-9D18345C-DF43-4E0E-AE9E-1B9E2BE9480A

P31

Q40176521-D3B879CA-F825-4A9C-B6CB-9BF3EAD0D289

P356

Q40176521-50B74AC0-D695-4A65-BDD3-1A617EC3674B

P433

Q40176521-D4CC376D-6C5E-41BF-9D5D-D5EC0B965456

P478

Q40176521-DD83DD3C-87F5-46DA-980D-10DFFE26E070

P577

Q40176521-FEAF0E48-124D-4DE7-9494-3DFFA9A4560B

P698

Q40176521-592A2651-7E9D-4B55-8009-7E014EC69851

P356

1535-7163.MCT-06-0543

P1433

Molecular Cancer Therapeutics

P1476

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

@en

P2093

Daniel F Hassler

http://www.w3.org/2001/XMLSchema#string

Derek R Duckett

http://www.w3.org/2001/XMLSchema#string

Glenn M Spehar

http://www.w3.org/2001/XMLSchema#string

Kyle A Emmitte

http://www.w3.org/2001/XMLSchema#string

Masaaki Furuta

http://www.w3.org/2001/XMLSchema#string

Mui Cheung

http://www.w3.org/2001/XMLSchema#string

Nobuhiro Noro

http://www.w3.org/2001/XMLSchema#string

Randy T McConnell

http://www.w3.org/2001/XMLSchema#string

Robert A Mook

http://www.w3.org/2001/XMLSchema#string

Timothy J Lansing

http://www.w3.org/2001/XMLSchema#string

P304

450-459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-06-0543

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17267659

http://www.w3.org/2001/XMLSchema#string